|
|
Volumn 107, Issue 2, 2007, Pages 173-176
|
|
Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop
a
b
|
|
Author keywords
Approval; CA125; Cancer; Endpoints; FDA; Ovarian; Research; Therapy
|
|
Indexed keywords
CA 125 ANTIGEN;
ARTICLE;
CANCER STAGING;
CLINICAL RESEARCH;
DISEASE FREE SURVIVAL;
DRUG EFFICACY;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MEDICAL SOCIETY;
OUTCOME ASSESSMENT;
OVARY CANCER;
OVERALL SURVIVAL;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
BIOMEDICAL RESEARCH;
CA-125 ANTIGEN;
CLINICAL TRIALS AS TOPIC;
DISEASE-FREE SURVIVAL;
DRUG APPROVAL;
ENDPOINT DETERMINATION;
FEMALE;
GYNECOLOGY;
HEALTH STATUS;
HUMANS;
MEDICAL ONCOLOGY;
OVARIAN NEOPLASMS;
PATIENT SATISFACTION;
QUALITY OF LIFE;
SOCIETIES, MEDICAL;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 35348925113
PISSN: 00908258
EISSN: 10956859
Source Type: Journal
DOI: 10.1016/j.ygyno.2007.08.092 Document Type: Article |
|
Times cited : (58)
|
|
References (5)
|
